Karin Warfvinge Selected Research

U 0126 (UO 126)

1/2021	Combination treatment with U0126 and rt-PA prevents adverse effects of the delayed rt-PA treatment after acute ischemic stroke.
1/2019	MEK/ERK/1/2 sensitive vascular changes coincide with retinal functional deficit, following transient ophthalmic artery occlusion.
1/2017	Myocardial ischemia-reperfusion enhances transcriptional expression of endothelin-1 and vasoconstrictor ETB receptors via the protein kinase MEK-ERK1/2 signaling pathway in rat.
3/2015	U0126 attenuates cerebral vasoconstriction and improves long-term neurologic outcome after stroke in female rats.
1/2015	Modulation of inflammatory mediators in the trigeminal ganglion by botulinum neurotoxin type A: an organ culture study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karin Warfvinge Research Topics

Disease

20	Migraine Disorders (Migraine) 02/2022 - 01/2011
6	Headache (Headaches) 10/2020 - 01/2011
6	Ganglion Cysts (Ganglion) 03/2020 - 12/2009
6	Ischemia 01/2019 - 06/2009
4	Stroke (Strokes) 01/2021 - 02/2015
4	Pain (Aches) 01/2018 - 01/2011
3	Inflammation (Inflammations) 01/2017 - 12/2009
2	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 08/2017 - 02/2015
2	Retinal Vasculitis 01/2011 - 01/2006
1	Ischemic Stroke 01/2021
1	Retinal Detachment (Retinal Detachments) 03/2020
1	Vascular System Injuries 11/2019
1	Neuroinflammatory Diseases 01/2019
1	Headache Disorders (Headache Syndromes) 01/2019
1	Blindness (Hysterical Blindness) 01/2019
1	Reperfusion Injury 01/2017
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2017
1	Brain Ischemia (Cerebral Ischemia) 01/2016
1	Gliosis 01/2016
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 03/2015
1	Infarction (Infarctions) 03/2015
1	Cardiovascular Diseases (Cardiovascular Disease) 02/2015
1	Burns 01/2011
1	Retinal Degeneration 01/2002

Drug/Important Bio-Agent (IBA)

14	Calcitonin Gene-Related PeptideIBA 02/2022 - 01/2011
9	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA 01/2021 - 01/2011
6	Retinaldehyde (Retinal)IBA 03/2020 - 06/2009
5	U 0126 (UO 126)IBA 01/2021 - 01/2015
5	NeuropeptidesIBA 02/2020 - 01/2012
5	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 11/2019 - 01/2011
3	Oxytocin (Pitocin)FDA LinkGeneric 10/2021 - 02/2020
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 01/2017
3	Peptides (Polypeptides)IBA 10/2020 - 11/2018
3	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA 10/2020 - 11/2018
3	Neurotransmitter Agents (Neurotransmitter)IBA 01/2019 - 01/2016
3	AntibodiesIBA 01/2019 - 04/2010
2	Serotonin (5 Hydroxytryptamine)IBA 02/2022 - 01/2016
2	Hormones (Hormone)IBA 10/2021 - 02/2020
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2021
2	Pituitary Adenylate Cyclase-Activating Polypeptide ReceptorsIBA 01/2020 - 11/2018
2	MicroRNAs (MicroRNA)IBA 11/2019 - 02/2015
2	Protein Kinases (Protein Kinase)IBA 01/2019 - 01/2017
2	Endothelin-1 (Endothelin 1)IBA 01/2017 - 01/2016
1	Tryptamines (Triptans)IBA 02/2022
1	Gonadal Steroid Hormones (Sex Hormones)IBA 10/2021
1	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2021
1	Substance PIBA 01/2021
1	Matrix Metalloproteinases (MMPs)IBA 01/2021
1	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA 01/2021
1	Metalloproteases (Metalloproteinases)IBA 01/2021
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2021
1	Cyclin D1IBA 03/2020
1	Oxytocin Receptors (Oxytocin Receptor)IBA 02/2020
1	Receptor Activity-Modifying Protein 1IBA 01/2019
1	Calcitonin Receptor-Like ProteinIBA 01/2019
1	CytokinesIBA 01/2019
1	Type A Botulinum Toxins (Botox)FDA Link 11/2018
1	lasmiditanIBA 11/2018
1	Adenylyl Cyclases (Adenylyl Cyclase)IBA 11/2018
1	erenumabIBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	fremanezumabIBA 01/2018
1	eptinezumabIBA 01/2018
1	galcanezumabIBA 01/2018
1	ubrogepantIBA 01/2018
1	salicylhydroxamic acid (SHAM)IBA 01/2017
1	Amino Acids FDA Link 01/2017
1	Vasoconstrictor AgentsIBA 01/2017
1	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 12/2016
1	Vasodilator Agents (Vasodilators)IBA 01/2016
1	Endothelin Receptors (Endothelin Receptor)IBA 01/2016
1	Proteins (Proteins, Gene)FDA Link 01/2016
1	VimentinIBA 01/2016
1	Endothelins (Endothelin)IBA 03/2015
1	Biomarkers (Surrogate Marker)IBA 02/2015
1	incobotulinumtoxinA FDA Link 01/2015
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2015
1	MitogensIBA 01/2015
1	CalbindinsIBA 04/2010
1	RecoverinIBA 04/2010
1	TransducinIBA 04/2010
1	ParvalbuminsIBA 04/2010
1	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 12/2009
1	4-(2-oxapentadeca-4-yne)phenylpropanoic acidIBA 06/2009
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2002

Therapy/Procedure

9	Therapeutics 10/2021 - 08/2013
2	Transplantation 01/2011 - 01/2006
1	Drug Therapy (Chemotherapy) 02/2022
1	Lasers (Laser) 01/2011
1	Microspheres (Microsphere) 12/2009